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Abstract
Background: Inactivation of the p53 pathway that controls cell cycle progression, apoptosis and senescence, has been
proposed to occur in virtually all human tumors and p53 is the protein most frequently mutated in human cancer. However,
the mutational status of p53 in melanoma is still controversial; to clarify this notion we analysed the largest series of
melanoma samples reported to date.
Methodology/Principal Findings: Immunohistochemical analysis of more than 180 melanoma specimens demonstrated
that high levels of p53 are expressed in the vast majority of cases. Subsequent sequencing of the p53 exons 5–8, however,
revealed only in one case the presence of a mutation. Nevertheless, by means of two different p53 reporter constructs we
demonstrate transcriptional inactivity of wild type p53 in 6 out of 10 melanoma cell lines; the 4 other p53 wild type
melanoma cell lines exhibit p53 reporter gene activity, which can be blocked by shRNA knock down of p53.
Conclusions/Significance: In melanomas expressing high levels of wild type p53 this tumor suppressor is frequently
inactivated at transcriptional level.
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Introduction
p53, the ‘‘guardian of the genome’’, is a transcription factor that
can bind to promoter regions of hundreds of genes where it either
activates or suppresses gene expression [1]. Thereby, p53 serves as
a tumor suppressor by inducing cell cycle arrest, apoptosis,
senescence and DNA repair [2]. In normal cells, p53 is frequently
undetectable due to fast ubiquitination by mdm-2 and subsequent
proteasomal degradation [3]. However, upon DNA damage and
several other stresses, including oncogenic stress, the amount of
p53 is increased due to disruption of its degradation [4,5].
Notably, inactivation of p53 is one of the characteristics of cancer.
Indeed, p53 has a wide spectrum of mutation types and p53 is
found mutated in approximately half of all tumors [6]. Most of
these aberrations are missense mutations in the central DNA
binding domain disrupting the transcriptional capability and
conferring different degrees of dominance over co-expressed wild-
type p53 [7]. Alternatively, impairment of the p53 response to
oncogenic stress has been reported which is mediated via increased
degradation by viral proteins or mdm-2 overexpression [8,9].
Moreover, p53 induction may be affected for example by loss of
p14ARF [10]. On a post-translational level, the transcriptionally
activity of p53 can also be impaired by sequestration in the cytosol
[11], by competition for DNA-binding sites by DNp73 [12] or
functional antagonism with iASPP [13].
Recently, p53 has been suggested to be a major player suppressing
progression from nevi to melanoma [14]. Studies on the frequency of
p53 mutations in melanoma, however, reported relatively low but
quite divergent numbers ranging from 0 to 30% [15–20]. To address
this controversy we here evaluated a large series of more than 180
melanoma samples for p53 protein expression and genetic p53
mutations. Although p53 is generally expressed in melanoma tissues it
harbours only very rarely mutations. In contrast, in 4 of 14melanoma
cell lines p53 was found to be mutant. Notably, inmelanoma cell lines
which have preserved the p53 wild-type geno/phenotype observed in
situ, we demonstrate transcriptional inactivity of the protein in 6 out of
10 cell lines suggesting active silencing as the mode of p53 inactivation
in melanoma.
Results and Discussion
Expression of p53 in melanoma
Many tumors accumulate mutant p53 protein which is
explained by a lack of p53-dependent Mdm-2 induction leading
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to decreased proteasomal degradation [3]. Immunohistochemical
analysis of 185 melanoma samples demonstrated that in the
majority of tumors high levels of p53 are expressed in a
considerable proportion of the tumor cells (Figure 1 A and B).
Moreover, we observed an increase in p53 expression from
primary to metastatic tumors (Figure 1B), thereby confirming
previous reports [21].
Absence of p53 mutation in melanoma
p53 mutation frequencies of 21, 24 or 29% have been described
for melanoma tissues and short term melanoma cell cultures [17–
19]. Prompted by these reports and the finding that p53 was highly
expressed in situ, we started to analyze genomic DNA from a series
of 206 paraffin-embedded melanoma tissues by nested PCR
amplification and direct sequencing of the p53 exons 5–8; these
exons harbour 95% of the known p53 mutations [10]. All four,
three, two or only one exon were successfully amplified for 128,
34, 32 or 12 samples, respectively. In 26% of the samples, we
observed irreproducible PCR artefacts which pretended possible
mutations (Figure 2). However, a reproducible amino acid
substitution (P278R; C833G; heterozygous; GenBank accession
number: 573759) was only observed in one case (Figure 2). We do
not know whether sequencing results in studies observing higher
p53 mutation rates were controlled for reproducibility but
reported high frequencies of silent mutations as well as double
and triple mutations in one exon may be indicative of false
positives [18,19]. Furthermore, formalin-fixed paraffin-embedded
material as used in these studies (like in ours) is notorious for
generating PCR artefacts [22]. Based on carefully reproduced
sequencing results in this - to the best of our knowledge - largest
series studied to date, we now confirm previous reports describing
a virtual absence of p53 mutations in melanoma tissues [15,16,20].
However, we have to admit that there was a considerable fraction
of 78 samples for which we failed to amplify all 4 exons. Thus, we
do not know the complete sequence of the p53 mutation hot spot
region in this fraction of specimens. All primer binding sites,
however, were located in exon-flanking introns, thus, failure of
amplification does not indicate an altered coding sequence.
Moreover, as we could detect p53 expression in virtually all
corresponding tissues, inability of PCR amplification cannot be
due to loss of both p53 alleles. Most likely, failure of amplification,
is simply due to limited quality of the gDNA extracted from the
formalin-fixed and paraffin-embedded tissues. This is further
substantiated by the fact that for many of the respective DNAs not
only amplification of more than one p53 exon but also
amplification from other genes like BRAF and NRAS failed.
p53 mutations in melanoma cell lines
Notably, several of the previous studies on p53 mutations were
carried out in melanoma cell lines. Thus, we analysed the
mutational status of p53 in 14 melanoma cell lines by sequencing
all coding exons of p53. 4 of the 14 cell lines, i.e. BLM, IF-6,
Mel2a and FM55, harboured p53 mutations (Figure 3; GenBank
accession numbers 573755–573758). All of the mutations have
been described to be inactivating (http://www-p53.iarc.fr).
Interestingly, all four sequences lacked the corresponding wild
type signal indicating either homozygous mutation or more
probably loss of heterozygosity at the p53 locus. In line with this,
FM55 cells, where the mutation leads to a premature stop codon,
express only the truncated p53 protein indicated by increased
mobility in gel electrophoresis (Figure 3). Hence under culture
Figure 1. p53 expression in melanoma tissues. (A) Immunohis-
tochemical detection of p53 in a primary melanoma. (B) 104 primary
cutaneous and 81 metastatic melanoma samples were stained for p53.
The percentage of positively stained tumor cells is given as bar graph.
doi:10.1371/journal.pone.0022096.g001
Figure 2. Reproducibility of p53 sequencing. Sequencing
chromatograms depicting the only reproducible p53 mutation and an
example of an apparent mutation which could not be reproduced in an
independent PCR amplification from the same sample.
doi:10.1371/journal.pone.0022096.g002
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conditions melanoma cells tend to acquire inactivating p53
mutations although in situ mutant p53 is not favoured [15].
Absence of p53 reporter gene activity in 6 out of 10 wt
p53 melanoma cell lines
Most of the above-described melanoma cell lines express high
levels of p53 which are comparable to those found in melanoma
cells in situ. To understand why melanoma cells tolerate high levels
of wild type p53 expression we addressed the pertinent question
whether p53 is transcriptionally active in these cells. To this end, in
a first set of experiments 10 of the melanoma cell lines described
above were stably transfected with a PathDetectH reporter plasmid
coding for luciferase under the control of a p53 enhancer element.
As expected, the 4 melanoma cell lines harbouring inactivating p53
mutations did not show p53-dependent luciferase expression
(Figure 3). Surprisingly, however, among the 6 cell lines with wild
type p53 p53-dependent luciferase expression which could be
abolished upon shRNA knock down of p53 was only observed in
FM88 and MelJuso cells (Figure 3). The presence of the luciferase
DNA in the genome was confirmed by real time PCR for all 10 cell
lines (in Figure 3 the relative copy numbers are given on top of the
figure) and the functionality of the luciferase reporter could be
demonstrated in 8 of the cell lines as luciferase expression was
inducible upon transient ectopic expression of p53 (data not shown).
Thus, in 4 out of 6 cell lines which reflect the in situ p53 status, no
p53-dependent luciferase expression could be detected (Figure 3).
Since it is known that different p53 responsive elements are targeted
differentially by p53 depending on the cellular and environmental
Figure 3. Functional inactivity in 4 out of 6 melanoma cell lines expressing wild type p53 measured by the p53 reporter construct
PathDetectH. The p53 reporter construct PathDetectH encoding luciferase under the control of a p53 responsive element (146
TGCCTGGACTTGCCTGG) was transfected into the indicated melanoma cell lines. Following selection for a co-transfected puromycin resistence
integration of the luciferase gene was confirmed by real time PCR and the relative copy numbers are indicated (top row). The cells were then infected
with lentiviral supernatants carrying the shRNA expression construct KH1 containing either a scrambled or a sequence targeting p53 [41]. On Day 4
following infection the cells were harvested and lysates were subjected to a luciferase assay (upper part) or were analysed for expression of the
indicated proteins by western blot (lower part). Sequence analysis of all p53 coding exons revealed that four cell lines carried the indicated p53 amino
acid substitutions.
doi:10.1371/journal.pone.0022096.g003
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background [23] we tested a second reporter with a different p53
response element. As we, furthermore, aimed to analyze primary
melanocytes as an untransformed control we used the lentiviral
pGreenFire p53 reporter, which allowed efficient transduction of
melanocytes. In addition to four of the p53 wild type melanoma cell
lines analyzed by the PathDetect reporter in the first series of
experiments, human epidermal melanocytes (HEM) as well as four
short term melanoma cell lines carrying wild type p53 (Wu¨Mel)
were analyzed in this set of experiments. The results obtained with
the PathDetect p53 reporter were definitely reproduced with the
pGreenFire p53 reporter for FM88, MelJuso, Skmel28 and M26
(Figure 4). Out of the four Wu¨Mel cell lines Wu¨Mel48 and 74a -
which were proliferating only very slowly in vitro - displayed high,
p53 shRNA repressible, p53 reporter gene activity, although p53
was expressed at relatively low levels (Figure 4). In contrast,
Wu¨Mel45 and 49 were characterized by lack of p53 transcriptional
activity in the presence of high levels of wild type p53 (Figure 4). A
high level p53 transcriptional acitivity - almost comparable to those
observed in the melanoma cells - measured in HEMs suggests that
tolerating such p53 activities may be an intrinsic feature of
melanocytic cells.
The pGreenFire vector contains luciferase and GFP which are
both expressed under the control of a p53 responsive element.
Results obtained for GFP fluorescence analyzed by flow cytometry
(mean fluorescence intensity) and luciferase assays were highly
concordant, indeed (Figure 5 A and B). Moreover, as flow
cytometry allows analysis on a single cell level, we could exclude
that high reporter gene activity in melanocytes or in the respective
melanoma cell lines represents an average of high and low p53
activity in different sub-populations (Figure 5 B).
In order to rank the levels of p53 dependent luciferase/GFP
expression with regard to the growth-inhibitory function of p53,
we treated the cells with Nutlin-3a, a specific inhibitor of the p53
ubiquitinase mdm-2. This intervention induced both moderate
increases in p53 expression (Figure 5 C) and p53 transcriptional
activity (Figure 5 A and B); this moderate increase, however, was
associated with a clear cut cell cycle arrest for HEMs, FM88 and
MelJuso (Figure 5D). In contrast S-phase entry was not impaired
in the low level p53 activity melanoma cell lines (Figure 5 D). In
this context, SKmel28, Wu¨Mel45 and Wu¨Mel49 did not show an
increase in p53 expression suggesting that mdm-2 does not restrict
p53 expression in these cell lines (Figure 5C).
Figure 4. Functional inactivity in 4 out of 8 melanoma cell lines expressing wild type p53 measured by the p53 reporter construct
pGreenFireH. Human epidermal melanocytes and the indicated melanoma cell lines were stably transduced with a lentiviral pGreenFire reporter
construct encoding luciferase and GFP under the control of a p53 responsive element (46CGACATGCCCGGGCATGT). The cells were then infected
with lentiviral supernatants carrying the shRNA expression construct KH1 containing either a scrambled or a sequence targeting p53 [41]. On Day 4
following infection total cell lysates were analysed for p53 expression by immunoblotting (lower part). Equal loading was controlled by Ponceau S
staining of the blot. In the upper part the corresponding luciferase activity is depicted, normalized to the relative luciferase load of the cell lines
determined by Real time PCR.
doi:10.1371/journal.pone.0022096.g004
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In summary our data demonstrate that p53 mutations are at
best a rare event in melanoma in situ; still, strong protein
expression in melanoma tissue indicates aberrations of p53
activity. Accordingly, we demonstrate functional inactivation of
p53 in a considerable proportion (60%) of melanoma cell lines
characterized by wild type p53. This notion is corroborated by a
recent report of a gene expression profiling study which
demonstrates that p53 target genes are differentially expressed in
melanomas compared with nevi, strongly suggesting a dysfunc-
tional p53 [24]. Moreover, our results are consistent with the
reported UV response of melanoma cell lines [25]; i.e. despite p53
target gene induction, p53 DNA-binding activity was absent in
melanoma cells with wild type p53. Interestingly, the authors
further reported that p53 target genes were similarly induced in
cells with mutant p53, thereby suggesting a comparable functional
activity of the DNA damage pathway upon UV-irradiation in
melanoma cells with wild type and mutated p53.
Future studies will be required to determine the mechanisms which
lead to transcriptional inactivity of wild type p53 in melanomas.
Possibly it involves proteins known to inhibit p53 like iASPP, DNp73,
YB-1 or Parc through direct interaction [11–13,26]. Alternatively,
silencing might be achieved by posttranslational modifications. In this
respect phosphorylation, acetylation, methylation, sumoylation and
neddylation have been identified to impact p53 transcriptional activity
[27]. Especially acetylation has been shown to alter p53 target
specificity [28]. Recently Satyamoorthy and colleques reported that
impairment in DNA damage induced phosphorylation of p53 on
serine-376 may contribute to radioresistence of melanoma cells [29].
Moreover, the preservation and increase of wild type p53 expression
during melanoma progression may be indicative of a tumor
promoting function of functionally silenced wild type p53. Therefore,
cytoplasmic functions of transcriptionally inactive p53 should be
analysed since theymay either limit or promote tumor growth [30,31].
Materials and Methods
Ethics Statement
Written informed consent was obtained from all patients prior
to any of these measures and the study was performed in
adherence to the Declaration of Helsinki Principles. The medical
ethical committee of the Universita¨tsklinik Wu¨rzburg approved all
described studies. Generation of melanoma cell lines after written
consent from the patients was approved by the Institutional
Review Board of Wu¨rzburg University Hospital (Ethikkommission
der Medizinischen Fakulta¨t der Universita¨t Wu¨rzburg; sequential
study number 123/08_ff).
Tumor material and p53 sequencing. Paraffin-embedded
tumor samples from primary and metastatic melanomas were
obtained by surgical excision. All tumors had undergone routine
histology for diagnosis. The three immediately following slides
from the blocks were used for DNA extraction and the following
slides were used to confirm the presence of the lesion and for
immunohistochemistry.
Sequence analysis of p53 exons 5 to 8
Prior to DNA extraction adjacent normal tissue was macro-
scopically dissected. For sequencing (SeqLab; Go¨ttingen, Ger-
many) the p53 exons 5, 6 7 and 8 were amplified with BioTherm
Figure 5. Determination of p53 reporter activities associated with cell cycle arrest. The indicated cells stably transduced with the
pGreenFire reporter construct encoding luciferase and GFP under the control of a p53 reporter were cultured in the absence or presence of the mdm-
2 inhibitor Nutlin 3a. After 24 hours p53 expression (C), luciferase acitvity (A) and GFP fluorescence (B) were analyzed. Cell cycle analysis was
performed on day 2 of treatment and the percentage of cells in S-phase are depicted (D).
doi:10.1371/journal.pone.0022096.g005
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Taq polymerase (GenCraft, Mu¨nster, Germany) by semi-nested
PCR using the following primers which all target exon flanking
intron sequences:
Exon 5-1 GTGCCCTGACTTTCAACTCTG
Exon 5-2 ATCAGTGAGGAATCAGAGGC
Exon 5-3 (nested Primer) GGGCAACCAGCCCTGTCG
Exon 6-1 GCCTCTGATTCCTCACTGAT
Exon 6-2 GGAGGGCCACTGACAACCA
Exon 6-3 (nested Primer) CCAGAGACCCCAGTTG-
CAAAC
Exon 7-1 AGGCGCACTGGCCTCATCTT
Exon 7-2 AGGGGTCAGAGGCAAGCAGA
Exon 7-3 (nested Primer) TCAGAGGCAAGCAGAGGCTG
Exon 8-1 GGACAGGTAGGACCTGATTTCCTTAC
Exon 8-2 TGAATCTGAGGCATAACTGC
Exon 8-3 (nested Primer) TGCACCCTTGGTCTCCTC-
CAC
Sequences found to be affected by mutations were deposited at
Genbank.
Immunohistochemistry. 4 mm sections of paraffin-
embedded tumors were dried at 56uC and then treated twice
with xylene for 10 min at room temperature. Subsequently,
sections were washed twice with absolute ethanol and twice with
70% ethanol followed by one rinse with bi-distilled water. For
antigen retrieval, sections were incubated with citrate buffer
pH 9.0 (DAKO, Hamburg, Germany) for 10 min at 90uC and
rinsed with bi-distilled water. Next, slides were rinsed twice with
phosphate-buffered saline (PBS) and thereafter incubated with
Blocking Solution (DAKO, S2023) for 10 min at room
temperature. After two additional washing steps with PBS for
10 min at room temperature, the monoclonal a-p53 antibody
(DO-7, DAKO) was added to the sections in at a predetermined
concentration in PBS, followed by an over night incubation at
4uC. After two 10 min washes in PBS, biotinylated multispecies-
specific secondary antibody (DAKO, K5003) was added to the
sections for 30 min at room temperature. Slides were then washed
twice in PBS/bovine serum albumin, and bound antibodies were
visualized using streptavidin-HRP (DAKO K5003) and Vector
Vip (Vector Laboratories, Burlingame USA) as peroxidase
substrate according to the manufacturer’s guidelines. Finally, the
nuclei were stained with hemalaun.
Cell culture
Four melanoma cell lines (Wu¨Mel45, Wu¨Mel48, Wu¨Mel49 and
Wu¨Mel74a) were generated in our lab from melanoma metastasis
obtained from patients for diagnostic purposes, These cell lines as
well as the melanoma cell lines BLM [32] FM88 [33] IF-6 [34],
MV-3 [34] Mel2a [35] MelJuso [36] Skmel28 [37] FM55 [38]
M19 [39] and M26 [39] were grown in RPMI 1640 supplemented
with 10% fetal calf serum. Human epidermal melanocytes (HEM)
were purchased from PromoCell (Heidelberg, Germany) and
cultured in HAM’s F10 media, supplemented with 20% fetal
bovine serum, glutamine, ITS premix, 12-O-tetradecanoylphor-
bol-13-acetate, IBMX, and cholera toxin [40].
Transfection and infection
To establish cells with an integrated p53 reporter plasmid the
PathDetectH p53 cis-reporter gene construct (Strategene, La Jolla,
CA, USA), which codes for luciferase under the control of a p53
responsive element (146TGCCTGGACTTGCCTGG) as well as
a puromycin resistance plasmid (pBabe-puro) were co-transfected
in a ratio of 10/1. Then puromycin resistant cells were selected.
Integration of the luciferase gene was confirmed by PCR. The
second p53 reporter construct was the pGreenFire lentiviral vector
(SBI, Mountain View, Canada) which codes for a puromycin
resistence and for green fluorescent protein (GFP) as well as
luciferase under the control of a different p53 responsive element
(46CGACATGCCCGGGCATGT). Knock down of p53 protein
expression was achieved by a lentiviral shRNA expression
construct KH1 containing either a scrambled or a sequence
targeting p53 [41]. Infectious viruses were raised by transfecting
HEK293T [42] cells with the pGreenFire construct or the
respective KH1 vector and the helper constructs p59, p60 and
p61. Two days following transfection, virus supernatants were
harvested and filtered through 0.45 mm pore size filters. For
infection, virus-containing supernatants were supplemented with
4 mg/ml polybrene and then added to the target cells overnight.
Then medium was changed and the cells were cultured for 3 more
days prior to subjecting lysates of the cells to further analysis. Pure
populations carrying the pGreenFire reporter were selected by
culturing the cells in the presence of puromycin.
Real time PCR
To quantify the relative presence of the reporter constructs in the
transfected or infected cells a real time PCR assay for luciferase was
applied. Genomic DNA derived from the cell lines was analyzed
using TaqMan technology with primers (forward: 59- TTG GCA
GAA GCT ATG AAA CG -39; reverse: 59-GCA ACT GCA ACT
CCG ATA AA -39) and a respective probe (TP: FAM-CGC CCA
ACA CCG GCA TAA AGA -Tamra). By normalization to the
highly repetitive DNA elements LINE1 - for which the copy number
even in cancer cells is largely constant - a relative quantification of the
samples could be calculated by the DDCt method.
p53 reporter gene assay
Following 2 washes with PBS, triplicates of infected cells were
harvested by adding lysis buffer (10 mM NaCl, 8 mM tricine (ph
7.8), 0.4 mM EDTA, 1 mM DTT and 0.2%Triton X-100). After
shaking for 20 min at room temperature, the lysates were frozen
and stored at 220uC overnight. Upon thawing, the lysates were
centrifuged and 50 ml of supernatant was transferred to a
luminometer plate and luciferase acitivity was measured in an
Orion II luminometer (Berthold, Pforzheim, Germany) following
automatic injection of a luciferase buffer as previously described
[43]. Flow cytometry to monitor GFP expression in pGreenFire
transduced cells was performed on a FACSCanto (BD, Heidel-
berg, Germany).
Western blot analysis
Cells were lysed in Laemmli buffer and proteins were resolved
by SDS-polyacrylamid gel electrophoresis and transferred to
nitrocellulose membranes. Following blocking for 1 h with PBS
containing 0.05% Tween 20 and 5% powdered skim milk, blots
were incubated overnight with the primary antibody, washed three
times with PBS with 0.05% Tween 20, and then incubated with a
peroxidase coupled secondary antibody. Following extensive
washing, the bands were detected using a chemoluminescence
detection kit (Roche Diagnostics, Mannheim, Germany). Anti-
bodies to p53 (D-01) (Santa Cruz, Heidelberg, Germany) and b-
tubulin (Sigma, Ottobrunn, Germany) were used.
Cell cycle analysis
Cells were harvested and resuspended in 0.5 ml PBS supple-
mented with 1% fetal calf serum. Five ml of ice-cold EtOH was
added, followed by an over night incubation at 4uC. The fixed
cells were pelleted and resuspended in 1 ml PBS supplemented
with 1% fetal calf serum, 0.05 mg/ml propidium iodide, and
p53 in Melanoma
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0.1 mg/ml RNase A. Following a 1-hour incubation at 37uC,
analysis of the cellular DNA content was performed on a
FACSCanto flow cytometer.
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